Showing Results for
- Academic Journals (37)
Search Results
- 37
Academic Journals
- 37
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Jennifer Mitchell 1 2 3 , Allison Coker 1 4 , Berra Yazar-Klosinski 5 Author Affiliations: (1) Department of Neurology, University of California, San Francisco, San Francisco, USA (2) Department of...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedTalimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma. The present, ongoing study aimed to estimate the...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedNew strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B--a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach. Author(s):...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedA phase 1 trial shows the feasibility of a novel approach combining a powered hip exoskeleton with a passive leg prosthesis to improve the energy efficiency of walking. Author(s): Varun Nalam 1 2 , He (Helen) Huang 1 2...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedTo evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedIslatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that is in development for the prevention...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedFederated learning (FL) is a method used for training artificial intelligence models with data from multiple sources while maintaining data anonymity, thus removing many barriers to data sharing. Here we used data from...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Joar Øveraas Halvorsen 1 2 , Florian Naudet 3 , Ioana A. Cristea 4 Author Affiliations: (1) Department of Psychology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (2) St....
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedHuman immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind,...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Simar Singh Bajaj 1 , Alister Francois Martin 2 3 , Fatima Cody Stanford 4 5 6 7 Author Affiliations: (1) Department of the History of Science, Harvard University, Cambridge, USA (2) Department of...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAlterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Charlotte K. Boughton 1 2, Afroditi Tripyla 3, Sara Hartnell 2, Aideen Daly 1, David Herzig 3, Malgorzata E. Wilinska 1, Cecilia Czerlau 4, Andrew Fry 5, Lia Bally 3, Roman Hovorka 1 Author Affiliations:...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Ryan D. Schubert 1 2, Isobel A. Hawes 1 2, Prashanth S. Ramachandran 1 2, Akshaya Ramesh 1 2, Emily D. Crawford 3 4, John E. Pak 3, Wesley Wu 3, Carly K. Cheung 3, Brian D. O'Donovan 5, Cristina M. Tato 3, Amy...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed'Individualized therapy' trials (sometimes called n-of-1 trials) use patients as their own controls to evaluate treatments. Here we divide such trials into three categories: multi-crossover trials aimed at individual...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedSpinal muscular atrophy type 1 (SMA1) is a debilitating neurodegenerative disease resulting from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec (formerly AVXS-101) is a gene therapy that...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Viknesh Sounderajah 1 2 , Hutan Ashrafian 1 2 , Sherri Rose 3 , Nigam H. Shah 4 , Marzyeh Ghassemi 5 , Robert Golub 6 , Charles E. Kahn Jr 7 , Andre Esteva 8 , Alan Karthikesalingam 9 , Bilal Mateen 10 , Dale...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedEarly increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAuthor(s): Mohammad Ali 1 , Jafar Khan 1 , Nisar Ahmad 1 , Haji Khan 1 , Arshad Iqbal 1 , Muhammad Rizwan 1 , Murad Ali 1 , Bilal Haider Abbasi 2 Author Affiliations: (1) Centre for Biotechnology and Microbiology,...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedCytokine blockade can improve the survival rate of patients with COVID-19 who are at risk of respiratory failure, but timing and patient selection are key. Author(s): Randy Q. Cron 1 , Roberto Caricchio 2 , W. Winn...
-
From:Nature Medicine (Vol. 27, Issue 10) Peer-ReviewedAbove-knee amputation severely reduces the mobility and quality of life of millions of individuals. Walking with available leg prostheses is highly inefficient, and poor walking economy is a major problem limiting...